
Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer CellsAward last edited on: 12/11/2023
Sponsored Program
SBIRAwarding Agency
NSFTotal Award Amount
$274,975Award Phase
1Solicitation Topic Code
PTPrincipal Investigator
Marc GilligCompany Information
Enable Life Sciences LLC
One Mifflin Place Suite 400 Harvard Square
Cambridge, MA 02138
Cambridge, MA 02138
(617) 500-3252 |
contactenablelifesciences.com |
www.enablelifesciences.com |
Location: Single
Congr. District: 05
County: Worcester
Congr. District: 05
County: Worcester
Phase I
Contract Number: 2246487Start Date: 9/15/2023 Completed: 8/31/2024
Phase I year
2023Phase I Amount
$274,975Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00